Enzalutamide: Targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer - Abstract

CONTEXT: Significant progress has been made in the understanding of the underlying cancer biology of castration-resistant prostate cancer (CRPC) with the androgen receptor (AR) signalling pathway remaining implicated throughout the prostate cancer disease continuum.

Reactivation of the AR signalling pathway is considered to be a key driver of CRPC progression and, as such, the AR is a logical target for therapy in CRPC.

OBJECTIVE: To understand the importance of AR signalling in the treatment of patients with metastatic CRPC (mCRPC) and to discuss the clinical benefits associated with inhibition of the AR signalling pathway.

EVIDENCE ACQUISITION: A search was conducted to identify articles relating to the role of AR signalling in CRPC and therapies that inhibit the AR signalling pathway.

EVIDENCE SYNTHESIS: Current understanding of prostate cancer has identified the AR signalling pathway as a logical target for the treatment of CRPC. Available therapies that inhibit the AR signalling pathway include AR blockers, androgen biosynthesis inhibitors and AR signalling inhibitors. Enzalutamide, the first approved AR signalling inhibitor, has a novel mode of action targeting AR signalling at three key stages. The direct mode of action of enzalutamide has been shown to translate into clinical responses in patients with mCRPC.

CONCLUSIONS: The targeting of the AR signalling pathway in patients with mCRPC results in numerous clinical benefits. As the number of treatment options increase, more trials evaluating the sequencing and combination of treatments are required.

PATIENT SUMMARY: This review highlights the continued importance of targeting a key driver in the progression of CRPC, AR signalling, and the clinical benefits associated with inhibition of the AR signalling pathway in the treatment of patients with CRPC.

Written by:
Schalken J, Fitzpatrick JM.   Are you the author?
Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

Reference: BJU Int. 2015 Mar 27. Epub ahead of print.
doi: 10.1111/bju.13123


PubMed Abstract
PMID: 25818596

UroToday.com mCRPC Treatment Section

email news signup